

## national tay-sachs & allied diseases association

RESEARCH REVIEW: Special Edition

December 8, 2017

## 2017-2018 Request for Proposals

## Pre-applications due on January 12, 2018

This year, NTSAD will be joined by the Cure Tay-Sachs Foundation (CTSF) in this RFP. CTSF is a grassroots organization focused on funding Tay-Sachs research since its inception by parents just over ten years ago.



Grants will be awarded for an initial period of one year at up to \$40,000 direct costs per year (5% indirect cost rate); funding for a second year is predicated by adequate progress during year 1. The application will use a two-step process. First, a one page pre-application will be submitted. From these pre-applications, investigators will be chosen to submit a full application. The application format and review criteria are specified on page 2 of this RFP.



## The deadline for submission of one-page pre-applications is January 12, 2018.

We are soliciting proposals for innovative research projects that involve basic research, translational studies or clinical studies in the following diseases: Tay-Sachs, GM-1, Sandhoff, and Canavan disease. CTSF's funding interests will be only in Tay-Sachs disease. Basic research and translational studies should generate strong preliminary data to enable future major funding by other third parties. Projects may be in such areas as drug delivery to the brain, new animal models designed to facilitate translational research and drug discovery, assay development for drug screening, substrate reduction, stem

cells, molecular chaperones, gene therapy, and biomarkers, as well as exploring other novel therapeutic strategies.

In addition to soliciting proposals for novel research projects, we strongly encourage applicants to submit proposals that address one or more of the following: understanding disease progression and natural history as well as unmet needs from a patient perspective across the severity spectrum of any given indication, development of patient registries, translational biomarkers with clinical utility, measurable and clinically meaningful efficacy endpoints for clinical trials, clinical research networks, and newborn screening.

The pre-applications will be reviewed by sub-committees of NTSAD's Scientific Advisory Committee and Corporate Advisory Council. Selected applications will be invited to submit full applications for further peer review and funding consideration. Grant awards are based on proposal evaluation by a Research Evaluation Subcommittee of NTSAD's Scientific Advisory Committee. The grant awards will be announced in April. The funding period begins approximately on July 1, 2018, pending the Institution's agreement to NTSAD's Research Grant Policies.

Download (pdf) RFP Guidelines

NTSAD Past Grants

Susan Kahn, Executive Director

Blyth Lord, President, NTSAD Board

Staci Kallish, DO, Vice President, NTSAD Board

Fran Platt, PhD, Chair, Scientific Advisory Committee

& Allied Diseases Association

2001 Beacon Street, Suite 204

Boston, MA 02135

(617) 277-4463 | info@ntsad.org

www.NTSAD.org

**National Tay-Sachs**